NovaBridge Biosciences (FRA:0VY)
Germany · Delayed Price · Currency is EUR 1.170
-0.030 (-2.50%)
Last updated: Oct 23, 2026, 8:01 AM CEST
NovaBridge Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
141.91M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.40M | - |
| Dec 31, 2021 | 13.85M | -222.30M | -94.14% |
| Dec 31, 2020 | 236.15M | 231.84M | 5,381.18% |
| Dec 31, 2019 | 4.31M | -3.51M | -44.90% |
| Dec 31, 2018 | 7.82M | 6.04M | 340.20% |
| Dec 31, 2017 | 1.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Medios AG | 2.16B |
| MEDICLIN Aktiengesellschaft | 819.84M |
| Stratec SE | 244.81M |
| LIMES Schlosskliniken AG | 56.72M |
NovaBridge Biosciences News
- 20 hours ago - NovaBridge announces presentation of results from Phase 1b study of givastomig - TheFly
- 1 day ago - NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development - GlobeNewsWire
- 6 days ago - Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia - GlobeNewsWire
- 13 days ago - Wuhan Hiteck enters exclusive license agreement with Visara - TheFly
- 13 days ago - Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China - PRNewsWire
- 13 days ago - Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis - GlobeNewsWire
- 17 days ago - NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 - GlobeNewsWire
- 6 weeks ago - NovaBridge Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts